抗慢性淋巴细胞白血病新药venetoclax药理作用及临床评价被引量：1

Pharmacology and Clinical Evaluation of Venetoclax for the Treatment of Chronic Lymphocytic Leukemia

下载PDF

导出

摘要 venetoclax为首个选择性口服B淋巴细胞瘤-2(Bcl-2)蛋白抑制剂,研究证实其治疗复发/难治慢性淋巴细胞白血病(CLL)具有可控的安全性,总体及完全有效率高。2016年4月11日,美国食品药品管理局(FDA)批准venetoclax用于治疗携带17p缺失突变且曾接受过至少一种治疗的CLL。本综述主要介绍venetoclax药物作用机制、药物代谢动力学、疗效、安全性及临床研究进展。 Venetoclax,the first oral selective inhibitor of the prosurvival protein Bcl-2,has been approved for being used as monotherapy in patients with chronic lymphocytic leukaemia(CLL)with the17p deletion who have received at least one prior therapy by FDA.Venetoclax had high overall and complete response rates and manageable safety profile in patients with relapsed CLL.This article reviews the mechanism of action,the clinical pharmacology of venetoclax and its efficacy and safety profile in clinical studies.

作者张亚安任莉萍钮娴张晴晴周新月潘喆 ZHANG Yaan;REN Liping;NIU Xian;ZHANG Qingqing;ZHOU Xinyue;PAN Zhe(Department of Pharmaceutical and Chemical Engineering of Southeast University Chengxian College,Jiangsu Nanjing210088,China)

机构地区东南大学成贤学院制药与化学工程学院

出处《中国医药导刊》 2017年第11期1164-1167,共4页 Chinese Journal of Medicinal Guide

基金江苏省高等学校大学生实践创新训练计划项目(项目编号:201612689021X 项目名称:药物超分子包合作用及其应用研究) 东南大学成贤学院大学生实践创新训练计划项目(项目编号:yox1778 项目名称:生理药理学微信数字平台的设计与实现)

关键词 Venetoclax Bcl-2蛋白抑制剂慢性淋巴细胞白血病 Venetoclax Selective inhibitor of Bcl-2 Chronic lymphocytic leukemia

分类号 R96 [医药卫生—药理学]

引文网络
相关文献

参考文献1

1赵楠,周颖,赵侠,崔一民.治疗慢性淋巴细胞白血病新药obinutuzumab的药理作用及临床评价[J].中国新药杂志,2014,23(11):1227-1229. 被引量：4

二级参考文献10

1WANG LQ, KWONG YL, WONG FK, et al. Epigenetic inacti- vation of mir-34b/c in additon to mir-34a and DAPK1 in chronic lymphocytic leucemia [ J ]. J Transl Med, 2014,12 ( 1 ) : 52.
2陆翔,王小超,陈诗强,等.含氟达拉滨的化疗方案治疗慢性淋巴细胞白血病25例长期随访分析[J].中华临床医师杂志(电子版),2013,7(10):4576-4578.
3JAK M, VAN BOCHOVE GG, REITS EA, et al. CD40 stimula- tion sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101[J].Blood, 2011, 118(19):5178 - 5188.
4OWEN C, STEWART DA. Obinutuzumab for the treatment of lymphoproliferative disorders[ J]. Expert Opin Biol Ther, 2012, 12(3): 343 -351.
5HERTER S, HERTING F, MUNDIQL O, et al. Preclinical ac- tivity of the type I1 CD20 antibody GAI01 (obinutuzumab) com- pared with rituximab and ofatumumab in vitro and in xenograft models [ J ]. Mol Cancer Ther, 2013,12 ( 10 ) : 2031 - 2042.
6FDA. Gazyva (obinutuzumab) : US prescribing information[ EB/ OL]. (2014 -02 -28). Http://www. accessdata, fda. gov/ drugsaffda-docs/label/2013/125486 s0001 bl. pdf.
7GOEDE V, FISCHER K, BUSCH R, et al. Obinutuzumab plus ehlorambucil in patients with CLL and coexisting conditions[J]. N Engl J Med, 2014,370(12) :1101 - 1110.
8MORSCHHAUSER FA, CARTRON G, THIEBLEMONT C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study[ J]. J Clin Oncol,2013,31 (23) :2912 -2919.
922 studies found for: obinutuzumab [ EB/OL ]. ( 2014 - 02 - 28). http://www, clinicaltrials, gov/ct2/resuhs? term = obinutu- zumab.
10中国慢性淋巴细胞白血病的诊断与治疗指南（2011年版）[J].中华血液学杂志,2011,32(7):498-501. 被引量：56